NC
AGIO icon

NinePointTwo Capital’s Agios Pharmaceuticals AGIO Stock Holding History

NinePointTwo Capital’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-8,717
Closed -$244K – 261
2022
Q4 		$244K Buy
+8,717
New +$246K 0.1% 70

Other funds holding AGIO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

NinePointTwo Capital's AGIO Position: Q1 2023 in Review

NinePointTwo Capital sold out of Agios Pharmaceuticals (AGIO) in Q1 2023, closing a stake of 8,717 shares — an estimated $244K sold.

NinePointTwo Capital first reported a position in AGIO in Q4 2022 and held it in 1 quarter. The position peaked at $244K in Q4 2022. 163 funds tracked by Wall St. Rank hold AGIO as of Q1 2023.

  • NinePointTwo Capital reported no remaining Agios Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • NinePointTwo Capital sold 8,717 Agios Pharmaceuticals shares in Q1 2023, an estimated $244K.
  • NinePointTwo Capital first reported a position in Agios Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • NinePointTwo Capital's Agios Pharmaceuticals position peaked at $244K in Q4 2022.
  • 163 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2023.

Based on NinePointTwo Capital's 13F filing for Q1 2023, filed 15 May 2023.